Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 4/20 | 0.46 |
| ▸ | MMP2 | P08253 | 3/20 | 0.46 |
| ▸ | MMP1 | P03956 | 2/20 | 0.46 |
| ▸ | MMP3 | P08254 | 2/20 | 0.46 |
| ▸ | MMP8 | P22894 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PPIP5K2 | O43314 | 1/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL28801115 | 1.00 | FDPS (0.46) | FDPSMMP2MMP1MMP3MMP8 | |
| Phosphoric Acid SCHEMBL16093844 | 1.00 | FDPS (0.46) | FDPSMMP2MMP1MMP3MMP8 | |
| Phosphoric Acid SCHEMBL192007 | 1.00 | FDPS (0.46) | FDPSMMP2MMP1MMP3MMP8 | |
| Phosphoric Acid SCHEMBL1019439 | 1.00 | FDPS (0.46) | FDPSMMP2MMP1MMP3MMP8 | |
| Phosphoric Acid SCHEMBL9359318 | 1.00 | FDPS (0.46) | FDPSMMP2MMP1MMP3MMP8 | |
| Phosphoric Acid SCHEMBL21359160 | 1.00 | FDPS (0.46) | FDPSMMP2MMP1MMP3MMP8 | |
| Phosphoric Acid SCHEMBL23751823 | 0.97 | FDPS (0.43) | FDPSMMP2MMP1MMP3MMP8 | |
| Phosphoric Acid SCHEMBL8575235 | 0.97 | FDPS (0.43) | FDPSMMP2MMP1MMP3MMP8 | |
| Phosphoric Acid SCHEMBL28610245 | 0.97 | FDPS (0.43) | FDPSMMP2MMP1MMP3MMP8 | |
| Phosphoric Acid SCHEMBL28500444 | 0.97 | FDPS (0.43) | FDPSMMP2MMP1MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630586-B2 | Process for the preparation of plecanatide | AURO PEPTIDES LTD (IN) | 2026-05-19 | — | — | US | claimed |
| US-12577274-B2 | Manufacture of glucagon peptides | BACHEM HOLDING AG (CH) | 2026-03-17 | — | — | US | claimed |
| US-20260035406-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS | CARMOT THERAPEUTICS INC. (US) | 2026-02-05 | — | — | US | claimed |
| US-12528050-B2 | Biocide composition and method | JUSTEQ, LLC (US) | 2026-01-20 | — | — | US | claimed |
| EP-4665401-A1 | DRUG AND TREATMENT METHOD | RadioVaxx GmbH (DE) | 2025-12-24 | — | — | EP | claimed |
| CN-120022522-A | Drug-loaded microneedle, drug-loaded microneedle patch and electrically-controlled drug release microneedle system | 成都邦迈医创科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-119822677-A | Phosphogypsum reinforcing agent based on chip sludge and preparation and use methods thereof | 武汉理工大学 | 2025-04-15 | — | — | CN | claimed |
| US-20250114744-A1 | BIOCIDE COMPOSITION AND METHOD | ACCULAB CO., LTD. (KR) | 2025-04-10 | — | — | US | claimed |
| EP-4507722-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | Bluewillow Biologics, Inc. (US) | 2025-02-19 | — | — | EP | claimed |
| US-12201943-B2 | Biocide composition and method | JUSTEQ, LLC (US) | 2025-01-21 | — | — | US | claimed |
| WO-2007112505-A1 | GLYCERIDE ESTER DERIVATIVES OF HERBICIDAL COMPOUNDS AND COMPOSITIONS THEREOF | NUFARM AUSTRALIA LIMITED (AU) | 2007-10-11 | — | — | WO | claimed |
| WO-2007030885-A1 | AGROCHEMICAL EMULSIFIABLE CONCENTRATE | NUFARM AUSTRALIA LIMITED (AU) | 2007-03-22 | — | — | WO | claimed |
| WO-2004085453-A1 | SYNTHESIS AND METHOD OF PURIFICATION OF CYCLIC NUCLEOTIDE DERIVATIVES | PHARMACORE, INC. (US) | 2004-10-07 | — | — | WO | claimed |
| US-20030171536-A1 | PROCESS FOR PREPARING CARDIODILATIN FRAGMENTS; HIGHLY PURIFIED CARDIODILATIN FRAGMENTS AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF SAME | PHARIS BIOTEC GMBH (DE) | 2003-09-11 | — | — | US | claimed |
| EP-0763061-B1 | PROCESS AND INTERMEDIATE PRODUCTS FOR PREPARING CARDIODILATIN FRAGMENTS, AND HIGHLY PURIFIED CARDIODILATIN FRAGMENTS | FORSSMANN WOLF GEORG (DE) | 2002-10-30 | — | — | EP | claimed |
| EP-0763061-A1 | PROCESS AND INTERMEDIATE PRODUCTS FOR PREPARING CARDIODILATIN FRAGMENTS, AND HIGHLY PURIFIED CARDIODILATIN FRAGMENTS | Roche Diagnostics GmbH (DE) | 1997-03-19 | — | — | EP | claimed |
| WO-1995033769-A1 | PROCESS AND INTERMEDIATE PRODUCTS FOR PREPARING CARDIODILATIN FRAGMENTS, AND HIGHLY PURIFIED CARDIODILATIN FRAGMENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1995-12-14 | — | — | WO | claimed |
| EP-0233645-A2 | Purification of growth hormone releasing factor from yeast strains producing same | PHILLIPS PETROLEUM COMPANY (US) | 1987-08-26 | — | — | EP | claimed |
| US-4377482-A | Mobile phase for liquid chromatography | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1983-03-22 | — | — | US | claimed |
| US-4247328-A | TRISODIUM CITRATE, AMINE PHOSPHATES | VICKERS LIMITED (GB) | 1981-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577274-B2 | Manufacture of glucagon peptides | IAPP, GLP1R, GCG | FDPS 1389/4885MMP2 2941/4885MMP1 4366/4885 |
| US-12630586-B2 | Process for the preparation of plecanatide | VIP, NGLY1, IDUA | FDPS 3994/4885MMP2 1509/4885MMP1 684/4885 |
| US-20260035406-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS | GLP1R, GIPR, GRPR | FDPS 4260/4885MMP2 4178/4885MMP1 4817/4885 |
| US-12528050-B2 | Biocide composition and method | SLC6A12, SLC6A6, CLIC1 | FDPS 4876/4885MMP2 1747/4885MMP1 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.